Clinical Attribute

Regenxbio Reports Consistent One-Year Benefit for DMD Gene Therapy RGX-202

2 days ago talkbio0Tagged AFFINITY DUCHENNE trial, Biological Markers, Clinical Trials, Functional, gene therapy, Muscular Dystrophy, Duchenne, Phase III, Regenxbio, SLC6A8 Inhibitor RGX-202

Regenxbio; DMD; Duchenne muscular dystrophy; RGX-202; gene therapy; AFFINITY DUCHENNE trial; clinical trial; microdystrophin; biomarker; phase I/II; functional data

Precision Medicine’s Next Frontier: Unlocking the Power of Biospecimens

6 days ago talkbio0Tagged biobanking, Biological Markers, biospecimens, Cancer Genomics, Drug Development, Multiomics, Precision Medicine, spatial transcriptomics

precision medicine; biospecimens; multi-omics; drug development; biobanking; personalized medicine; biomarkers; spatial transcriptomics; cancer genomics

FDA Approves Novavax COVID Vaccine After Delay, Limits Use to Smaller High-Risk Population

3 weeks ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), Health conditions:-:Point in time:^Patient:-, Novavax, Nuvaxovid, protein-based vaccine, restricted population, United States Food and Drug Administration, Vaccines

Novavax; FDA approval; COVID-19 vaccine; Nuvaxovid; restricted population; protein-based vaccine; older adults; underlying health conditions

Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI

3 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Biological Markers, Boehringer Ingelheim, Cancer Research, Discover, Drug Development, Neoplasms, real-world data, strategic collaboration, Tempus AI

Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration

Revolutions KRAS drugs appear competitive in several lung cancer settings

4 weeks ago talkbio0Tagged Biological Markers, G12C inhibitors, K-ras Oncogene, KRAZATI, Lumakras, Non-Small Cell Lung Carcinoma, Rotation, sotorasib

KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

1 month ago talkbio0Tagged 95%, gene therapy, Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular

Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular, gene therapy, 95%

France pauses chikungunya vaccinations in the elderly after patient death

1 month ago talkbio0Tagged Adverse event, Age, Chikungunya Fever, Disease Outbreaks, Elderly (population group), France, Latex Fixation Tests, older, Reunion Island, Vaccination, Vaccines

Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination

Keytruda around head and neck cancer surgery cuts chance of disease coming back

1 month ago talkbio0Tagged Episodic, Head, Keytruda, perioperative

Keytruda, Head, perioperative, Episodic

Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

4 months ago talkbio0Tagged Boehringer, FIBRONEER-ILD, Force, Idiopathic Pulmonary Fibrosis, Ingelheim, nerandomilast, Phase 3 Clinical Trials, Progressive, Pulmonary Fibrosis, Respiratory physiology, Vital capacity

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

Biomarker Data’s Potential to Expedite Approval of Edgewise’s Dystrophy Drug

6 months ago talkbio0Tagged Becker, Biological Markers, Drug Development, regulatory approval

Biomarkers, drug development, Edgewise Therapeutics, Becker muscular dystrophy, regulatory approval